ABN AMRO Bank N.V. Has $773,000 Stock Position in Abbott Laboratories $ABT

ABN AMRO Bank N.V. trimmed its position in Abbott Laboratories (NYSE:ABT) by 96.8% during the first quarter, HoldingsChannel.com reports. The fund owned 7,513 shares of the healthcare product maker’s stock after selling 224,139 shares during the quarter. ABN AMRO Bank N.V.’s holdings in Abbott Laboratories were worth $773,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Brighton Jones LLC increased its stake in shares of Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after buying an additional 4,755 shares during the period. Sivia Capital Partners LLC raised its position in Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after buying an additional 162 shares during the last quarter. United Bank boosted its holdings in Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after acquiring an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC increased its stake in shares of Abbott Laboratories by 13.6% during the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock worth $1,618,000 after purchasing an additional 1,428 shares during the last quarter. Finally, Canada Pension Plan Investment Board grew its holdings in Abbott Laboratories by 25.6% during the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock valued at $195,267,000 after purchasing an additional 292,547 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Daniel J. Starks bought 10,000 shares of the business’s stock in a transaction on Monday, April 27th. The stock was acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction on Thursday, April 23rd. The shares were acquired at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ABT. Evercore dropped their price target on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Raymond James Financial lowered their price target on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Piper Sandler restated an “overweight” rating and set a $115.00 price target on shares of Abbott Laboratories in a research note on Monday, June 22nd. Citigroup cut their price objective on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a report on Friday, April 17th. Finally, Weiss Ratings cut Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, June 16th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $118.30.

Abbott Laboratories Price Performance

NYSE:ABT opened at $94.02 on Monday. The firm has a market capitalization of $163.77 billion, a price-to-earnings ratio of 26.34, a P/E/G ratio of 1.62 and a beta of 0.63. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The stock has a fifty day moving average of $89.08 and a 200 day moving average of $105.27. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter last year, the company posted $1.09 EPS. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, research analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 70.59%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.